{"id":"https://openalex.org/W2806138002","doi":"https://doi.org/10.1002/cpdd.576","title":"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluations Following Single Oral Doses of GSK2330672 in Healthy Japanese Volunteers","display_name":"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluations Following Single Oral Doses of GSK2330672 in Healthy Japanese Volunteers","alternate_titles":[],"publication_year":2018,"publication_date":"2018-06-05","ids":{"openalex":"https://openalex.org/W2806138002","doi":"https://doi.org/10.1002/cpdd.576","mag":"2806138002","pmid":"https://pubmed.ncbi.nlm.nih.gov/29870578"},"language":"en","primary_location":{"id":"doi:10.1002/cpdd.576","doi":"https://doi.org/10.1002/cpdd.576","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cpdd.576","pdf_url":null,"source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2806138002"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5029238349","display_name":"Hiroko Ino","orcid":"https://orcid.org/0000-0002-6793-7944","observed_orcids":["https://orcid.org/0000-0002-6793-7944"]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Hiroko Ino","raw_affiliation_strings":["GlaxoSmithKline Development & Medical Affairs Division Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline Development & Medical Affairs Division Japan","institution_ids":["https://openalex.org/I4210115149"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Akira Endo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Akira Endo","raw_affiliation_strings":["GlaxoSmithKline Development & Medical Affairs Division Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline Development & Medical Affairs Division Japan","institution_ids":["https://openalex.org/I4210115149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074805741","display_name":"Akira Wakamatsu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Akira Wakamatsu","raw_affiliation_strings":["GlaxoSmithKline Development & Medical Affairs Division Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline Development & Medical Affairs Division Japan","institution_ids":["https://openalex.org/I4210115149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053078432","display_name":"Hirofumi Ogura","orcid":"https://orcid.org/0000-0002-8042-6495","observed_orcids":["https://orcid.org/0000-0002-8042-6495"]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hirofumi Ogura","raw_affiliation_strings":["GlaxoSmithKline Development & Medical Affairs Division Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline Development & Medical Affairs Division Japan","institution_ids":["https://openalex.org/I4210115149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035170485","display_name":"Yotaro Numachi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210115149","display_name":"GlaxoSmithKline (Japan)","ror":"https://ror.org/01j6sxy67","country_code":"JP","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210115149"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yotaro Numachi","raw_affiliation_strings":["GlaxoSmithKline Development & Medical Affairs Division Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline Development & Medical Affairs Division Japan","institution_ids":["https://openalex.org/I4210115149"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5058944613","display_name":"Stuart F. W. Kendrick","orcid":"https://orcid.org/0000-0002-0804-5743","observed_orcids":["https://orcid.org/0000-0002-0804-5743"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4405268060","display_name":"GlaxoSmithKline Research & Development Limited (United Kingdom)","ror":"https://ror.org/05mayyh83","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405268060"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Stuart Kendrick","raw_affiliation_strings":["GlaxoSmithKline Research & Development Stevenage UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline Research & Development Stevenage UK","institution_ids":["https://openalex.org/I188950975","https://openalex.org/I4405268060"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5029238349"],"corresponding_institution_ids":["https://openalex.org/I4210115149"],"apc_list":{"value":3800,"currency":"USD","value_usd":3800},"apc_paid":null,"fwci":0.6101,"has_fulltext":false,"cited_by_count":12,"citation_normalized_percentile":{"value":0.68416246,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"8","issue":"1","first_page":"70","last_page":"77"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.5303000211715698,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.5303000211715698,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11834","display_name":"Liver Diseases and Immunity","score":0.4325999915599823,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.007699999958276749,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ileal-bile-acid-transporter-inhibitors","display_name":"ileal bile acid transporter inhibitors","score":0.8830000162124634},{"id":"https://openalex.org/keywords/primary-biliary-cholangitis","display_name":"primary biliary cirrhosis","score":0.8180000185966492},{"id":"https://openalex.org/keywords/cholestatic-pruritus","display_name":"cholestatic pruritus","score":0.9359999895095825},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8149999976158142},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9900000095367432},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.9070000052452087},{"id":"https://openalex.org/keywords/single-oral-dose","display_name":"single oral dose","score":0.7490000128746033},{"id":"https://openalex.org/keywords/fecal-occult-blood","display_name":"fecal occult blood","score":0.6200000047683716},{"id":"https://openalex.org/keywords/serum-bile-acids","display_name":"serum bile acids","score":0.7599999904632568},{"id":"https://openalex.org/keywords/7alpha-hydroxy-4-cholesten-3-one","display_name":"7\u03b1-hydroxy-4-cholesten-3-one","score":0.9390000104904175},{"id":"https://openalex.org/keywords/japanese-volunteers","display_name":"Japanese volunteers","score":0.6639999747276306}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9329085350036621},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.868808925151825},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.7431308627128601},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.7182918787002563},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.6845637559890747},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.667705237865448},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5943809151649475},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.5547983646392822},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5444821119308472},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.49986696243286133},{"id":"https://openalex.org/C2779802037","wikidata":"https://www.wikidata.org/wiki/Q40878","display_name":"Diarrhea","level":2,"score":0.4714185893535614},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4198874235153198},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.41531333327293396},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.05949324369430542},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002352","descriptor_name":"Carrier Proteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D002783","descriptor_name":"Cholestenones","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008562","descriptor_name":"Membrane Glycoproteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D008744","descriptor_name":"Methylamines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D008744","descriptor_name":"Methylamines","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008744","descriptor_name":"Methylamines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D008744","descriptor_name":"Methylamines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013841","descriptor_name":"Thiazepines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013841","descriptor_name":"Thiazepines","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D013841","descriptor_name":"Thiazepines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D013841","descriptor_name":"Thiazepines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D044466","descriptor_name":"Asian People","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/cpdd.576","doi":"https://doi.org/10.1002/cpdd.576","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cpdd.576","pdf_url":null,"source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},{"id":"pmid:29870578","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29870578","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology in drug development","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W1657692460","https://openalex.org/W1836306145","https://openalex.org/W1979543957","https://openalex.org/W1989086831","https://openalex.org/W2041297399","https://openalex.org/W2087577664","https://openalex.org/W2088633095","https://openalex.org/W2089526803","https://openalex.org/W2093292173","https://openalex.org/W2094285893","https://openalex.org/W2106191318","https://openalex.org/W2108571956","https://openalex.org/W2122717283","https://openalex.org/W2130289643","https://openalex.org/W2146626180","https://openalex.org/W2152758419","https://openalex.org/W2229648568","https://openalex.org/W2290381682","https://openalex.org/W2342384916","https://openalex.org/W2518389324","https://openalex.org/W2586480777","https://openalex.org/W2591813770","https://openalex.org/W2786456523","https://openalex.org/W2789204053"],"related_works":["https://openalex.org/W7220938763","https://openalex.org/W7221159621","https://openalex.org/W2522654891","https://openalex.org/W2586480777","https://openalex.org/W2500163800","https://openalex.org/W4231504287","https://openalex.org/W2913532420","https://openalex.org/W2793137643","https://openalex.org/W4415639271","https://openalex.org/W4322617864"],"abstract_inverted_index":{"GSK2330672":[0,55,69,117,178],"is":[1,17],"an":[2],"inhibitor":[3],"of":[4,54,68,123,145,154,159,163,177],"the":[5,48,121,157],"ileal":[6],"bile":[7,134,146],"acid":[8,147],"transporter,":[9],"designed":[10],"to":[11,46,86,136,149],"have":[12],"minimal":[13],"systemic":[14],"exposure,":[15],"and":[16,31,51,81,102,108,112,138],"under":[18],"development":[19],"as":[20],"a":[21,129,142],"potential":[22,164],"therapeutic":[23],"for":[24,131,139,166],"pruritus":[25,168],"associated":[26],"with":[27,151],"primary":[28],"biliary":[29],"cholangitis":[30],"other":[32],"cholestatic":[33,167],"liver":[34],"diseases.":[35],"A":[36],"phase":[37],"1,":[38],"double-blind,":[39],"placebo-controlled,":[40],"4-period":[41],"crossover":[42],"study":[43,87],"was":[44,118],"conducted":[45],"evaluate":[47],"safety,":[49],"tolerability,":[50],"pharmacokinetic/pharmacodynamic":[52],"characteristics":[53],"in":[56,74,120,169,179],"healthy":[57,61],"Japanese":[58,180],"participants.":[59],"Sixteen":[60],"male":[62],"participants":[63],"received":[64],"single":[65],"oral":[66],"doses":[67,153],"(10-180":[70],"mg)":[71],"or":[72,89],"placebo":[73],"each":[75],"period.":[76],"No":[77],"serious":[78],"adverse":[79,83,94],"events":[80,84,95],"no":[82],"leading":[85],"discontinuation":[88],"withdrawal":[90],"were":[91,109],"reported.":[92],"Drug-related":[93],"reported":[96],"included":[97,128],"gastrointestinal":[98],"symptoms":[99],"(mostly":[100],"diarrhea)":[101],"positive":[103],"fecal":[104],"occult":[105],"blood":[106],"tests,":[107],"all":[110],"mild":[111],"resolved":[113],"without":[114],"any":[115],"interventions.":[116],"undetectable":[119],"majority":[122],"participants'":[124],"plasma.":[125],"Pharmacodynamic":[126],"observations":[127],"tendency":[130],"total":[132],"serum":[133,140],"acids":[135],"reduce":[137],"7\u03b1-hydroxy-4-cholesten-3-one,":[141],"key":[143],"intermediate":[144],"synthesis,":[148],"increase":[150],"increasing":[152],"GSK2330672.":[155],"In":[156],"context":[158],"recently":[160],"published":[161],"indications":[162],"efficacy":[165],"non-Japanese":[170],"populations,":[171],"these":[172],"data":[173],"support":[174],"further":[175],"evaluations":[176],"patients.":[181]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2806138002","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":2},{"year":2018,"cited_by_count":1}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2018-06-13T00:00:00"}
